Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 6
Submit an article Journal homepage
527
Views
2
CrossRef citations to date
0
Altmetric
Letter to the Editor

Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma

Frank HertingRoche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Munich, Germany; View further author information
,
Thomas FriessRoche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Munich, Germany; View further author information
,
Pablo UmañaRoche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Zurich, Switzerland; View further author information
,
Steven MiddletonRoche Pharmaceutical Research and Early Development, Roche Innovation Center New York, New York, USAView further author information
&
Christian KleinRoche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Zurich, Switzerland; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-7594-7280View further author information
ORCID Icon
Pages 1482-1485 | Received 03 Apr 2017, Accepted 30 Aug 2017, Published online: 15 Sep 2017

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Christian Klein, Candice Jamois & Tina Nielsen. (2021) Anti-CD20 treatment for B-cell malignancies: current status and future directions. Expert Opinion on Biological Therapy 21:2, pages 161-181.
Read now

Articles from other publishers (1)

Christian Klein, Ekkehard Mössner, Marina Bacac, Günter Fingerle-Rowson & Pablo Umaña. 2018. Successful Drug Discovery. Successful Drug Discovery 245 289 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.